Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours, Policy Position Statement (PPS315), November 2025 (PDF, 423Kb)
Ataluren for treating Duchenne Muscular Dystrophy with a nonsense mutation in the dystrophin gene, Policy Position Statement (PP118), July 2023.pdf (PDF, 217Kb)
Belimumab for treating active autoantibody-positive systemic lupus erythermatosus in people aged 5-17 years, Policy Position Statement (PPS317), November 2025 (PDF, 396Kb)
Belimumab for treating active autoantibody-positive systemic lupus erythermatosus in people aged 5-17 years, Policy Position Statement (PPS317), November 2025 (PDF, 396Kb)
Berotralstat for preventing recurrent attacks of hereditary angioedema for people aged 12 years and older, Policy Position Statement (PP236). June 2022.pdf (PDF, 277Kb)
Birch bark extract for treating epidermolysis bullosa in people aged 6 months and older, Policy Position Statement (PPS284), December 2024.pdf (PDF, 398Kb)
Dexrazoxane for Preventing Cardiotoxicity in Children (Aged Under 16 Years Old) Receiving High-Dose Anthracyclines or Related Drugs for the Treatment of Cancer, Policy Position Statement (PP253), February 2023 (PDF, 265Kb)
Drug treatments for seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in people aged 2 years and older, Policy Position Statement (PPS203), April 2025.pdf (PDF, 397Kb)
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency in people aged 18 months and over, Policy Position Statement (PP281), February 2024.pdf (PDF, 212Kb)
Emicizumab as prophylaxis in people with congenital haemophilia A with factor VIII inhibitors (all ages), Policy Position Statement (PPS167), September 2025.pdf (PDF, 459Kb)
Evinacumab for the treatment of homozygous familial hypercholesterolaemia in people aged 12 years and over, Policy Position Statement (PPS308), July 2025.pdf (PDF, 437Kb)
Nusinersen for treating children and young people up to 17 years old with spinal muscular atrophy, Policy Position Statement (PPS191), August 2025.pdf (PDF, 485Kb)